Objective: To review the safety, efficacy, and tolerability of vonoprazan for the treatment of Helicobacter pylori infection in adults. Data Sources: A literature search was performed through PubMed using the following key terms: vonoprazan, Voquezna, TAK-438, potassium-competitive acid blocker, H pylori, and gastrointestinal. Study Selection and Data Extraction: Selected articles included those which described clinical studies of the pharmacology, pharmacokinetics, efficacy, safety, or tolerability of vonoprazan. Data Synthesis: Vonoprazan works by competing with potassium on the proton pump to inhibit gastric acid secretion. Phase 3 clinical trials have shown that vonoprazan is noninferior to proton pump inhibitors (PPIs) as a component of H pylori eradication regimens. Vonoprazan has also shown promise in duodenal ulcer-healing rates and in reducing symptoms of heartburn. Common adverse effects associated with vonoprazan include nasopharyngitis, diarrhea, constipation, flatulence, dyspepsia, headache, and abdominal pain. Conclusion: Clinical practice guidelines recommend PPIs as the antisecretory agent of choice in H pylori eradication regimens with histamine-2 receptor antagonists (H2RAs) as potential alternatives. However, the use of either class of medications may be limited by adverse effects, drug interactions, and tolerability. Potassium-competitive acid blockers (P-CABs), like vonoprazan, may be safe and effective alternative antisecretory agents for H pylori eradication regimens, as well as other gastrointestinal disorders.
Centers for Disease Control and Prevention (CDC). Helicobacter pylori: fact sheet for health care providers. CDC. Accessed December 8,2022. https://stacks.cdc.gov/view/cdc/40603.
CheyWDLeontiadisGIHowdenCWMossSF.ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212-238. doi:10.1038/ajg.2016.563.
4.
Voquezna. Package insert. Florham Park, NJ: Phathom Pharmaceuticals; 2022
5.
Abdel-AzizYMetzDCHowdenCW.Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021;53(7):794-809. doi:10.1111/apt.16295.
6.
KeelingDJTaylorAGSchudtC.The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine3-acetonitrile, to the gastric (H+ + K+)-ATPase. J Biol Chem. 1989;264(10):5545-5551.
7.
HoriYImanishiAMatsukawaJ, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231-238. doi:10.1124/jpet.110.170274.
8.
MulfordDJLeifkeEHibberdMHowdenCW.The effect of food on the pharmacokinetics of the potassium-competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev. 2022;11(2):278-284. doi:10.1002/cpdd.1009.
9.
JenkinsHSakuraiYNishimuraA, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636-648. doi:10.1111/apt.13121.
10.
Drug approval review for vonoprazan fumarate (in Japanese), the pharmaceuticals and medical devices agency of Japan. 2014. Accessed December 12, 2022. https://www.pmda.go.jp/.
11.
ShinJMInatomiNMunsonK, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridine-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethenamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339(2):412-420. doi:10.1124/jpet.111.185314.
LaineLSharmaPMulfordDJ, et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol. 2022;117(7):1158-1161. doi:10.14309/ajg.0000000000001735.
14.
The interview form for vonoprazan fumarate (Takecab tablets 10 mg and 20 mg) ver.S, (in Japanese). Takeda Pharmaceutical. 2015. http://www.takeda.co.jp/.
15.
Prescribing information of Takecab tablets 10 mg and 20 mg ver.2 (in Japanese). 2015. Accessed December 12, 2022. http://www.takeda.co.jp/.
16.
HouXMengFWangJ, et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. J Gastroenterol Hepatol. 2022;37(7):1275-1283. doi:10.1111/jgh.15837.
17.
KinoshitaYSakuraiYTakabayashiN, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 2019;10(11):e00101. doi:10.14309/ctg.0000000000000101.
18.
XiaoYZhangSDaiN, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with a erosive oesophagitis. Gut. 2020;69(2):224-230. doi:10.1136/gutjnl-2019-318365.
19.
LaineLDeVaultKKatzP, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61-71. doi:10.1053/j.gastro.2022.09.041.
20.
CheyWDMégraudFLaineLLópezLJHuntBJHowdenCW.Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022;163(3):608-619. doi:10.1053/j.gastro.2022.05.055.
AngDKooSHChanYH, et al. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther. 2022;56(3):436-449. doi:10.1111/apt.17070.
23.
Garnock-JonesKP.Vonoprazan: first global approval. Drugs. 2015;75(4):439-443. doi:10.1007/s40265-015-0368-z.
24.
YangCLiSHuangT, et al. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2022;47(7):897-904. doi:10.1111/jcpt.13637.
NishiharaMYamasakiHCzerniakRJenkinsH.In vitro assessment of potential for CYP-inhibition-based drug-drug interaction between vonoprazan and clopidogrel. Eur J Drug Metab Pharmacokinet. 2019;44(2):217-227. doi:10.1007/s13318-018-0521-7.
